Denali Therapeutics Files 8-K for Shareholder Votes & Financials

TL;DR

Denali Therapeutics filed an 8-K on 5/31 for shareholder votes and financials.

AI Summary

Denali Therapeutics Inc. filed an 8-K on May 31, 2024, to report on matters submitted to a vote of security holders and to file financial statements and exhibits. The filing does not contain specific details on the votes or financial statements themselves, but indicates their submission.

Why It Matters

This filing signals that Denali Therapeutics has held or is reporting on shareholder votes and has submitted its financial statements, which are key disclosures for investors.

Risk Assessment

Risk Level: low — This is a routine filing to report on shareholder votes and financial statements, not indicating any specific new risks or material events.

Key Players & Entities

• Denali Therapeutics Inc. (company) — Registrant
• May 31, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share DNLI Nasdaq Global Select Mar

Filing Documents

• dnli-20240531.htm (8-K) — 42KB
• 0001714899-24-000125.txt ( ) — 163KB
• dnli-20240531.xsd (EX-101.SCH) — 2KB
• dnli-20240531_lab.xml (EX-101.LAB) — 21KB
• dnli-20240531_pre.xml (EX-101.PRE) — 12KB
• dnli-20240531_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On May 31, 2024, Denali Therapeutics Inc. (the "Company") held its annual meeting of stockholders. Of the 142,539,529 shares of common stock outstanding as of April 5, 2024, the record date for the meeting, 118,315,456 shares of common stock were represented at the meeting in person or by proxy, constituting 83.0% of the outstanding common stock entitled to vote. The matters voted upon at the meeting and the vote with respect to each such matter are set forth below: Proposal 1 - Election of Directors Election of three Class I directors to hold office until the 2027 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal. Nominees For Withheld Broker Non-Votes Jay Flatley 108,094,205 2,149,100 8,072,151 Mac Tessier-Lavigne, Ph.D. 82,215,374 28,027,931 8,072,151 Nancy A. Thornberry 108,270,582 1,972,723 8,072,151 Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting: For Against Abstain Broker Non-Votes 117,978,800 297,039 39,617 — Proposal 3 - Advisory Vote to Approve Executive Compensation The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 101,612,037 8,587,858 43,410 8,072,151

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI THERAPEUTICS INC. Date: May 31, 2024 By: /s/ Alexander O. Schuth Alexander O. Schuth, M.D. Chief Operating and Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR